- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04523116
Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1 (VALTIVE1)
Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: Optimising the Design of a Subsequent Randomised Discontinuation Trial: VALTIVE1
Tumours require a blood supply to provide them with oxygen and nutrients and to enable spread of cancer through blood vessels to other organs (metastasis). The formation of new blood vessels is known as angiogenesis, which is controlled by a growth factor (like a hormone) called Vascular Endothelial Growth Factor (VEGF). Many drugs have been developed that block VEGF and, in most tumour types, including ovarian cancer, the addition of VEGF inhibitors (VEGFi) to conventional anti-cancer therapy postpones recurrence of the disease. In ovarian cancer, VEGFi improve the overall outcome from the cancer in patients who have advanced stage and high-risk disease. VEGFi are now widely used in cancer medicine, yet until now there have not been any biomarkers (tests) that could be used to tell patients and their doctors whether the drugs were working or not. This is important, as VEGFi have side effects that are unpleasant for the patient. Additionally, VEGFi treatments are expensive.
The VALTIVE team has discovered the first biomarker that informs doctors whether a VEGFi is blocking a tumour's blood supply. The test involves measuring a protein in the blood called Tie2, which can be measured from routine blood tests that patients have when going to the hospital. If the test shows that the amount of Tie2 decreases in the blood, it means that tumour blood vessels are blocked by VEGFi; if, on the contrary, the level increases, the blood vessels have escaped the control of VEGFi.
The investigators have shown that the Tie2 test works in their initial studies in ovarian and bowel cancer. In these studies, the Tie2 blood test was based in the research laboratories. The investigators now wish to establish the test in the Christie Hospital NHS Biochemistry laboratory in Manchester so that it can be used in clinical practice rather than just as a research tool. The investigators wish to measure the relationship between loss of control of VEGF inhibitors as measured by TIE 2 and other standard ways of measuring loss of control of the tumour like increases on CT scans. There are several reasons why this test is needed for patients with ovarian cancer:
- VEGFi are effective during a patient's first or subsequent treatments for advanced ovarian cancer, but it is not clear which individuals are benefitting from treatment whilst they are on treatment.
- Patients who have already had one course of VEGFi can be re-treated successfully.
- Patients can avoid needless side effects, if there is a way of demonstrating that the treatment is of no benefit to them.
- This test will help doctors choose the best drug to control ovarian cancer and how long to continue treatment. This is very important, since other maintenance therapies are now available and the optimal duration of VEGFi therapy is well known.
- Around the world many teams are developing new combination treatments including VEGFi. If these new combinations prove effective, it would be possible to use them as efficiently as possible, as they will be very expensive and may therefore be less accessible to patients.
These issues highlight the critical need to establish a test in the NHS that tells patients and their doctors when VEGFi are working and when they stop working.
In VALTIVE1 study, blood samples will be taken from patients who are receiving a VEGFi called bevacizumab for ovarian cancer. Patients' management will not change during their participation to the trial. The analysis of the blood sample will support the hypothesis that patients whose Tie2 level decreases in response to bevacizumab will have ovarian cancer that is controlled for much longer than those where the Tie2 level does not decrease. These results will be used to design a second trial where the investigators will prove conclusively the value of the Tie2 test.
The purpose of VALTIVE1 is to optimise sample acquisition time points and analytical algorithms to support the design of VALTIVE2, a randomised discontinuation trial. In VALTIVE2, Tie2-defined, vascular non-responding patients will be randomly allocated to stop bevacizumab after 9 weeks, by when a response can be detected, or to continue bevacizumab for the conventional year of treatment.
Both VALTIVE 1 and VALTIVE2 will test the theory that there is no advantage in continuing bevacizumab in a patient whose Tie2 level does not reduce in response to VEGFi.
Study Overview
Status
Conditions
Detailed Description
VALTIVE1 is a multi-centre, single arm, non-interventional biomarker study, which will enrol 176 participants who are 16 years or older and who have FIGO stage IIIc/ IV ovarian cancer on treatment with first-line platinum-based chemotherapy and bevacizumab. Potential participants will be identified at their treating hospital.
The definition of vascular response is either (i) stable or reduced concentrations of Tie2 after 6 weeks of treatment or (ii) a confirmed reduction in plasma Tie2 of >10% within 9 weeks of starting treatment.
Patients enrolled into the VALTIVE 1 study will provide blood samples twice before treatment with bevacizumab and then at the end Cycles 1, 2, and 3, at the end of cytotoxic chemotherapy, at 3 months, 6 months, 9 months, at the end of treatment, and at disease progression. The early samples will be used to refine the definition and number of required samples needed to define a Tie2-vascular response. Samples collected at 3 months, 6 months, 9 months, at the end of treatment, and at disease progression will be used to investigate the relationship between Tie2-defined vascular progression and RECIST1.1- or clinically-defined Progression Disease (PD).
While the patients receive single agent maintenance bevacizumab, patients will undergo RECIST1.1 scanning at 3 months, 6 months, 9 months, end of treatment and at disease progression, if not before. These scans will also be reported to RECIST 1.1.
Progressive disease will be defined by the date of radiological or clinically identified progressive disease or death.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Margherita Carucci, PhD
- Phone Number: +442920687900
- Email: VALTIVE@cardiff.ac.uk
Study Locations
-
-
-
Bath, United Kingdom
- Recruiting
- Royal United Hospitals Bath NHS Foundation Trust
-
Contact:
- Rebecca Bowen
-
Manchester, United Kingdom
- Recruiting
- The Christie NHS Foundation Trust
-
Contact:
- Gordon Jayson
-
Northwood, United Kingdom
- Recruiting
- East and North Hertfordshire NHS Trust
-
Contact:
- Marcia Hall
-
Southampton, United Kingdom
- Recruiting
- University Hospital Southampton NHS Foundation Trust
-
Contact:
- Clare Green
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Potential participants will be under the care of a consultant who specialises in the treatment of ovarian cancer.
Patients who have been diagnosed with stage III/IV ovarian cancer within the routine clinics of participating centres and identified as requiring treatment with bevacizumab will be approached and screened.
Description
Inclusion Criteria:
In order to be eligible for participation in this trial, the patient must:
- Be willing and able to provide written informed consent for the trial
- Age 16 years or over on day of signing informed consent
- 3. Histologically proven ovarian, primary peritoneal or fallopian tube cancer (henceforth referred to collectively as Ovarian Cancer - OC) FIGO stage III with residual disease of more than 1cm; or stage IV; or stage III at presentation treated with neoadjuvant chemotherapy; or stage III with contraindication to debulking surgery chemotherapy
- Planned to receive treatment with bevacizumab or biosimilar bevacizumab
- Be scheduled to receive at least 2 successive doses of bevacizumab with 6 or more weeks of follow up blood samples after the first dose of bevacizumab if given pre-operatively; or to start bevacizumab post-operatively
- Be eligible for receiving treatment with first line, 3-weekly carboplatin and paclitaxel chemotherapy
- Be willing to provide blood samples and comply with trial-specific procedures
Exclusion Criteria:
The patient must be excluded from participating in the trial if the patient:
- Is unsuitable for treatment with VEGF inhibitors
- Is unable or unwilling to comply with study procedures
- Is participating in a clinical study with an investigational product other than carboplatin, paclitaxel and bevacizumab
- Is judged by the investigator to be unlikely to comply with study procedures
- Is pregnant or could become pregnant and is not using adequate contraception
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g. HCV RNA is detected). Testing only required if patient has a history of either of these
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: Up to 12 months after completion of the last Participant's follow up visit
|
To establish the validity of the Tie2 test as measured by progression free survival by showing the difference in terms of PFS between Tie2 vascular responders and Tie2 vascular non- responders.
|
Up to 12 months after completion of the last Participant's follow up visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Definition of Tie2 defined vascular response Definition of Tie2 defined vascular response Definition of Tie2 defined vascular response Definition of Tie2 defined vascular response
Time Frame: Up to 12 months after completion of the last Participant's follow up visit
|
To optimise the definition of Tie2-defined vascular response by analysing its relation with progression free survival as measured according to Response Evaluation Criteria in Solid Tumors(RECIST) v1.1 criteria.
|
Up to 12 months after completion of the last Participant's follow up visit
|
Optimum number of blood samples
Time Frame: Up to 12 months after completion of the last Participant's follow up visit
|
To define the optimum number of blood samples that need to be taken and tested for informing doctors whether their patients are responding to treatment (low level of Tie2) or are likely to progress (high level of Tie2).
|
Up to 12 months after completion of the last Participant's follow up visit
|
Relation between surgery and Tie2
Time Frame: Up to 12 months after completion of the last Participant's follow up visit
|
Patients with advanced ovarian cancer have surgery which stimulates the formation of new blood vessels and, consequently, may increase the level of Tie2 in the blood.
The measurement of Tie level in blood samples to be taken from 2 weeks before surgery until 4 weeks after surgery will show whether the surgery has any impact on plasma Tie2 concentrations.
|
Up to 12 months after completion of the last Participant's follow up visit
|
Design of the subsequent trial, VALTIVE2
Time Frame: Up to 12 months after completion of the last Participant's follow up visit
|
The definition of vascular response as assessed by measurement of Tie2 levels in plasma and its relation with PFS as per RECIST criteria will be validated in the randomised discontinuation non-inferiority trial VALTIVE2.
|
Up to 12 months after completion of the last Participant's follow up visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gordon Jayson, PhD, FRCP, University of Manchester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A29832
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovary Cancer
-
Health Science Center of Xi'an Jiaotong UniversityRecruitingOvarian Cancer | Cancer of the Ovary | Ovarian Neoplasm | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Ovary Neoplasm | Cancer of Ovary | Cancer, Ovarian | Ovarian Cancers | Neoplasm, Ovarian | Neoplasm, Ovary | Neoplasms, Ovary | Cancer, Ovarian Stromal | Cancers, Ovary | Ovary Cancers | Cancers, OvarianChina
-
Washington University School of MedicineCompletedOvarian Cancer | Cancer of the Ovary | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Cancer of OvaryUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); University of Pittsburgh; AIM ImmunoTech Inc.SuspendedOvarian Cancer | Cancer of the Ovary | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Cancer of OvaryUnited States
-
South Plains Oncology ConsortiumTerminatedOvarian Cancer | Cancer of the Ovary | Primary Peritoneal Carcinoma | Ovary Neoplasms | Cancer of OvaryUnited States
-
Ain Shams UniversityUnknown
-
Nuvation Bio Inc.RecruitingBreast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Breast Carcinoma | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Cancer of the Ovary | Pancreas Cancer | Triple-negative Breast Cancer | Cancer of Pancreas | Pancreas Neoplasm | Prostate Neoplasm | Cancer... and other conditionsUnited States, Australia
-
Parc de Salut MarCompleted
-
Faculdade de Ciências Médicas da Santa Casa de...Federal University of Paraíba; Irmandade da Santa Casa de Misericordia de Sao...Active, not recruitingLaparoscopy | Hemostasis | Endometriosis Ovary | Ovary; Functional DisturbanceBrazil
-
Memorial Sloan Kettering Cancer CenterRecruitingOvarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Stage III Fallopian Tube Cancer | Stage II Ovary Cancer | Stage II Ovarian Cancer | Stage III Ovary Cancer and other conditionsUnited States
-
University of Texas Southwestern Medical CenterAstraZenecaTerminatedFallopian Tube Cancer | Primary Peritoneal Carcinoma | Recurrent Epithelial Cancer of OvaryUnited States